Armata Pharmaceuticals Inc ARMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
-
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
-
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
-
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
-
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
-
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $7.56
- Day Range
- $7.23–8.05
- 52-Week Range
- $1.74–16.34
- Bid/Ask
- $6.30 / $9.40
- Shares Outstanding
- 36.70M
- Market Cap
- $274.23M
- Volume/Avg
- 66,534 / 60,269
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 61
- Website
- https://www.armatapharma.com
Valuation
|
Metric
|
ARMP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARMP
|
|---|---|
Quick Ratio | 0.52 |
Current Ratio | 0.64 |
Interest Coverage | −14.26 |
Quick Ratio
ARMP
Profitability
|
Metric
|
ARMP
|
|---|---|
Return on Assets (Normalized) | −339.28% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −347.14% |
Return on Assets
ARMP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Pfjmdjnp | Ngsltfk | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rgmynvvj | Lrskq | $63B | |||
| argenx SE ADR
ARGX
| Dcxkcbhdn | Brxcc | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hvkqltfsc | Jprhzh | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Wyqytdsp | Cmtgzyd | $24B | |||
| BioNTech SE ADR
BNTX
| Zkxqbtkp | Gmtb | $22B | |||
| Incyte Corp
INCY
| Xrwgqjnr | Rdfdb | $21B | |||
| Moderna Inc
MRNA
| Vwjgbkv | Wmlm | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Tnkyjkkph | Bhtj | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Dzygtgh | Zwxs | $13B |
United States